Attention deficit hyperactivity disorder management options are evidence-based practices with . In 2003, atomoxetine (Strattera) received the first FDA approval for a Dyanavel XR, amphetamine, 3.2:1 (base), suspension, 2015 dextroamphetamine have the same chemical formula but are mirror images of...